Skip to main content
. 2025 Dec 25;22(1):54–60. doi: 10.4274/ejbh.galenos.2025.2025-8-6

Table 1. The sociodemographic data of the patients.

Age mean (SD) (min-max)

56.85 (11.19) (33–80)

BMI mean (SD)

 median (Q1; Q3)

28.73 (4.76)

28 (25.43; 32.22)

Occupation

n (%)

Homemaker

54 (66.7%)

Civil servant

11 (13.6%)

Retired

11 (13.6%)

Self-employed

5 (6.2%)

Educational status

n (%)

Primary

37 (45.7%)

Elementary

10 (12.3%)

Highschool

24 (29.6%)

University

10 (12.3%)

Smoking

n (%)

Yes

12 (14.8%)

No

69 (85.2%)

Physical activity

n (%)

Sedentary

1 (1.2%)

Walks for pleasure

42 (51.9%)

Regular activity

26 (32.1%)

Sportive activity

12 (14.8)

Alcohol intake

n (%)

Yes

12 (14.8%)

No

69 (85.2%)

Pack years of smoking

mean (SD) (min-max)

4.56 (11.64) (0–5)

Breast cancer diagnosis yrs.

mean (SD) (min-max)

6.01 (5.51) (0.50–22)

Surgery

n (%)

Breast conservative surgery

Mastectomy

42 (51.9%)

39 (48.1%)

Lymph node dissection n (%)

Yes

45 (55.6%)

No

36 (44.4%)

Metastasis

n (%)

Yes

21 (25.9%)

No

60 (74.1%)

Radiotherapy

n (%)

Yes

66 (81.5%)

No

15 (18.5%)

Hormonetherapy

n (%)

Yes

63 (77.8%)

No

18 (22.2 %)

Lymphedema duration

mean (SD) (min-max)

1.65 (2.42) (0–10)

Lymphedema stage

n (%)

Stage 0/No clinical lymphedema*

41 (50.6%)

Stage 1

23 (28.4%)

Stage 2

14 (17.3%)

Stage 3

3 (3.7 %)

n: number of patients; SD: Standard deviation; min: Minimum; Max: Maximum

*It is well established that microscopic changes occur in the lymphatic system of patients who have undergone breast cancer treatment, conferring a lifelong risk of clinical lymphedema. To emphasize this, patients with no clinical symptoms were graded as stage 0/no clinical lymphedema.